^
Association details:
Biomarker:No biomarker
Cancer:Non-Hodgkin’s Lymphoma
Drug:carmustine (DNA synthesis inhibitor, Alkylating agent)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
05/16/2022
Excerpt:
Carmustine for Injection is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following...Relapsed or refractory non-Hodgkin's lymphomas in combination with other approved drugs...
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: A1 - Approval
Published date:
07/18/2018
Excerpt:
Carmustine is effective in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):…Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease...